Golf Clap for Bristol-Myers Squibb

Before you go, we thought you'd like these...
Before you go close icon

Bristol-Myers Squibb (NYSE: BMY) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Bristol-Myers Squibb met expectations on revenues and earnings per share.

Compared to the prior-year quarter, revenue contracted significantly and GAAP earnings per share dropped significantly.

Margins shrank across the board.

Revenue details
Bristol-Myers Squibb notched revenue of $4.44 billion. The 13 analysts polled by S&P Capital IQ predicted a top line of $4.43 billion on the same basis. GAAP reported sales were 18% lower than the prior-year quarter's $5.43 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.48. The 16 earnings estimates compiled by S&P Capital IQ forecast $0.48 per share. GAAP EPS of $0.38 for Q2 were 27% lower than the prior-year quarter's $0.52 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 72.0%, 110 basis points worse than the prior-year quarter. Operating margin was 23.1%, 1,030 basis points worse than the prior-year quarter. Net margin was 14.2%, 240 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $3.96 billion. On the bottom line, the average EPS estimate is $0.40.

Next year's average estimate for revenue is $17.88 billion. The average EPS estimate is $1.93.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,660 members out of 1,774 rating the stock outperform, and 114 members rating it underperform. Among 462 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 444 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $34.85.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners